Professor Ann Logan BSc, PGCE, PhD

Professor of Molecular Neuroscience

Neurotrauma and Neurodegeneration

Logan,Ann-Cropped-110x146

Contact details

School of Clinical and Experimental Medicine
College of Medical and Dental Sciences
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

Qualifications

  • PhD Neuroendocrinology
  • PGCE
  • BSc 1st Class (Hons) Botany/Zoology

Biography

Ann Logan received her BSc from the University of London, UK in 1974 and PhD training in neuroendocrinology from the University of Birmingham, UK between 1975 and 1978. 

After post-doctoral training at the University of Leeds, UK and in the laboratories of Professor Roger Guillemin and Professor Andrew Baird at Scripps Hospital, La Jolla, CA, she established the Molecular Neuroscience Group at the University of Birmingham in 1990, where she is currently Professor of Molecular Neuroscience and Head of the Neuropharmacology & Neurobiology Section within the School of Clinical and Experimental Medicine. 

Her research interests centre on the role of cytokines and growth factors in the scarring and regeneration responses of the injured CNS. She is particularly interested in developing a strategy of gene therapy to promote functional repair and reconstruction of damaged neural pathways in the CNS.

Teaching

  • BMedSc Molecular Medicine and Molecular Neuroscience options
  • MBChB 3rd year Neuroscience lectures
  • MBChB 2nd and 3rd year SSM – Lectures and extended essays in Neurodegeneration.
  • PgR Professional Training Programme

Postgraduate supervision

Currently supervises 6 PhD students

Research

Neurodegeneration and repair of the damaged and diseased central nervous system. Using cellular and molecular techniques to investigate the role of growth factors in the scarring and regeneration responses after brain and spinal cord injury. Developing a strategy of gene therapy to promote functional reconstruction of damaged neural pathways in the damaged CNS.

Other activities

  • International Spinal Research Committee – Member Scientific Advisory Board
  • International Spinal Research Committee – Member Programme Organising Committee
  • Society for Endocrinology – Member Awards Committee
  • Society for Endocrinology – Member Finance Committee
  • British Society for Gene Therapy – Founder member and Steering Group
  • British Society for Gene Therapy – Executive Board
  • Endocrinology – Editorial Board
  • Current Opinion in Pharmacology – Section Editor (Endocrinology and Metabolism)
  • Co-founder and Director of a University of Birmingham spin-out company called “Neuregenix”, whose mission is contract research and licensing of technologies patented by the academic team

Publications

Vigneswara V, Akpan N, Berry M, Logan A, Troy CM and Ahmed Z (2014) Combined suppression of caspase-2 and caspase-6 protects retinal ganglion cells from apoptosis and promotes axon regeneration through CNTF-mediated JAK/STAT signalling. Brain [Epub ahead of print]

Ahmed Z, Bansal D, Tizzard K, Surey S, Esmaeili M, Gonzalez AM, Berry M and Logan A (2014) Decorin blocks scarring and cystic cavitation in acute and induces scar dissolution in chronic spinal cord woundsNeurobiol Dis 64:163-76

Chan SY, Hancox LA, Martín-Santos A, Loubière LS, Walter MN, Gonzalez AM, Cox PM, Logan A, McCabe CJ, Franklyn JA and Kilby M (2014) MCT8 in human fetal cerebral cortex is reduced in severe intrauterine growth restrictionJ Endocrinol 220(2):85-95

Di Pietro V, Amorini AM, Tavazzi B, Vagnozzi R, Logan A, Lazzarino G, Signoretti S, Lazzarino G and Belli A (2014) The molecular mechanisms affecting n-acetylaspartate homeostasis following experimental graded traumatic brain injuryMol Med 20(1):147-57

Vigneswara V, Berry M, Logan A and Ahmed Z (2013) Caspase-2 is upregulated after sciatic nerve transection and its inhibition protects dorsal root ganglion neurons from apoptosis after serum withdrawal. Plos One 8(2)e57861

Vigneswara V, Berry M, Logan A and Ahmed Z (2013) Pigment epithelium-derived factor is retinal ganglion cell neuroprotective and axogenic after optic nerve crush injury. Invest Ophthalmol Vis Sci 54(4):2624-33

Ahmed Z, Douglas MR, John G, Berry M and Logan A (2013) AMIGO3 is an NgR1/p75 co-receptor signalling axon growth inhibition in the acute phase of adult central nervous system injury. PLoS One 8(4):e61878

Botfield H, Gonzalez AM, Abdullah O, Skjolding AD, Berry M, McAllister JP 2nd and Logan A (2013) Decorin prevents the development of juvenile communicating hydrocephalus. Brain  136(Pt 9):2842-58

Blanch RJ, Good PA, Shah P, Bishop JR, Logan A and Scott RA (2013) Visual outcomes after blunt ocular trauma. Ophthalmology 120(8):1588-91

Morgan-Warren PJ, Berry M, Ahmed Z, Scott RA and Logan A (2013) Exploiting mTOR Signaling: A Novel Translatable Treatment Strategy for Traumatic Optic Neuropathy? Invest Ophthalmol Vis Sci 54(10):6903-16

Mead B, Logan A, Berry M, Leadbeater W and Scheven BA (2013) Intravitreally transplanted dental pulp stem cells promote neuroprotection and axon regeneration of retinal ganglion cells after optic nerve injury. Invest Ophthalmol Vis Sci 54(12):7544-56

Expertise

Role of growth factors in scarring and neuron regeneration responses of injured mammalian brain and spinal cord; gene therapy to promote functional reconstruction of damaged neural pathways

Back to top